Nomikos Michael, Papanikolaou Sarantis, Athanasopoulos George, Papatsoris Athanasios
Department of Urology, Thriassion General Hospital, Athens, Greece.
Department of Urology, Sismanoglio University Hospital of Athens, Greece.
Cent European J Urol. 2017;70(3):301-305. doi: 10.5173/ceju.2017.1218. Epub 2017 Jun 23.
To present the outcomes of using Amplatz renal dilators in the management of complex urethral strictures.
From September 2011 to August 2015, 34 patients with complex urethral strictures were treated with Amplatz renal dilators assisted with internal urethrotomy. Evaluation included uroflowmetry, IPSS and post-void residual volume measurement. Under spinal anesthesia, sequential dilatations were performed with Amplatz renal dilators measuring from 8 Fr up to 24 Fr. Urethrotomy was sequentially performed.
The mean stricture length was 2.6 (1.5-3.5) cm. Preoperative mean Qmax was 4.4( 3.2-9.6) ml/sec. From September 2011 to August 2015, 34 patients with complex urethral strictures were treated with Amplatz renal dilators assisted with internal urethrotomy. Evaluation included uroflowmetry, IPSS and post- void residual volume measurement. Under spinal anesthesia, sequential dilatations with Amplatz renal dilators over an 8 Fr stylet were performed up to 24 Fr. Urethrotomy was sequentially performed. PVR was 155 (75-380) ml. Postoperative mean Qmax at 1 month was 18.4 (14.6-21.8) ml/sec, p <0.001, at 6 months was 16.6 (9.8-18.2) ml/sec, p <0.003 and at 12 months was 12.7 (7.4-17.3) ml/sec, p <0.005. Accordingly, mean PVR was significantly improved postoperatively, at 32 (12-88) ml in 1 month, p <0.001, while at 6 months was 34 (28-101) ml, p <0.005 and at 12 months was 62 (38-115) ml, p <0.005. Only 8 patients (23.5%) had a stricture recurrence in the first nine months and were treated with Amplatz dilatations alone.
The use of Amplatz renal dilators in combination with internal urethrotomy is a safe and effective technique for the endoscopic treatment of complex urethral strictures in patients unfit for reconstructive surgery.
介绍使用安普乐兹肾扩张器治疗复杂性尿道狭窄的结果。
2011年9月至2015年8月,34例复杂性尿道狭窄患者接受了安普乐兹肾扩张器辅助内尿道切开术治疗。评估包括尿流率测定、国际前列腺症状评分(IPSS)和排尿后残余尿量测量。在脊髓麻醉下,使用8F至24F的安普乐兹肾扩张器进行序贯扩张,并依次进行内尿道切开术。
狭窄平均长度为2.6(1.5 - 3.5)cm。术前平均最大尿流率(Qmax)为4.4(3.2 - 9.6)ml/秒。2011年9月至2015年8月,34例复杂性尿道狭窄患者接受了安普乐兹肾扩张器辅助内尿道切开术治疗。评估包括尿流率测定、IPSS和排尿后残余尿量测量。在脊髓麻醉下,通过8F探子使用安普乐兹肾扩张器进行序贯扩张至24F,并依次进行内尿道切开术。残余尿量(PVR)为155(75 - 380)ml。术后1个月平均Qmax为18.4(14.6 - 21.8)ml/秒,p<0.001;6个月时为16.6(9.8 - 18.2)ml/秒,p<0.003;12个月时为12.7(7.4 - 17.3)ml/秒,p<0.005。相应地,术后平均PVR显著改善,1个月时为32(12 - 88)ml,p<0.001;6个月时为34(28 - 101)ml,p<0.005;12个月时为62(38 - 115)ml,p<0.005。仅8例患者(23.5%)在最初9个月内出现狭窄复发,仅接受了安普乐兹扩张治疗。
对于不适合进行重建手术的患者,使用安普乐兹肾扩张器联合内尿道切开术是一种安全有效的内镜治疗复杂性尿道狭窄的技术。